)The top 100 stock
market authors
selected for publication in the last week
market authors
selected for publication in the last week
topicviewer
»
Comments
» Single Comment
| 
-
The Seeking Alpha 100
See all
Seeking Alpha 100 » -
Fastest Climbers
Those with the largestSee all
increase in followers
in the last week
Fastest Climbers » -
Top Commenters
Top commenters,See all
as ranked by their peers
Top Commenters » -
Top Instabloggers
The 100 most activeSee all
Instabloggers.
Top Instabloggers » -
Top StockTalkers
TopSee all
StockTalkers.
Top StockTalkers »
-
From the evening wires:
May 28 18:57 pm
|Rating:
0
0
All Comments by topicviewer »Peregrine Pharmaceuticals May Be On To Something [View article]
Just got picked for an oral presentation at the Society of Nuclear Medicine Annual Meeting to be held June 13-18, 2009. More than 65 patients with recurrent GBM have received Cotara in the current and previous clinical studies. Localization and accumulation of the drug to the tumor have been excellent and longer-term survivors (greater than one year from the time of Cotara treatment) have been observed in all of the trials, with some GBM patients from early clinical studies now alive more than 8.5 years after treatment with Cotara. Expected survival for patients with GBM is approximately six months from time of disease recurrence.
Also an Oral at ASCO
Time to revisit?